• Company has kept manufacturing facilities open during Lockdown and stepped up production of essential medical devices
  • Supply chain has been expanded 40% to support quicker deliveries and access healthcare facilities in remote parts of the country
  • Ramped up stock of critical product codes required for child birth and emergency surgeries

Bengaluru, India, July 07,2021

Healthium Medtech, a global leader in medical devices, today announced that it has strengthened its operations to fast track delivery of essentialmedical devices as the country fights the ongoing battle against COVID-19. In order to address the country’s need for essential medical consumables, Healthium Medtech has scaled its production, extended its supply chain and fast-tracked the deliveries of essential medical devices and consumables to support healthcare frontline workers.

To ensure adequate supply of medical devices for healthcare practitioners, the company is running its plants during lockdown with due permissions and pre-cautionary measures. The company has also expanded supply chain by 40% to fast track critical deliveries.

Considering the surge in demand for gloves at hospitals across the country, the company has utilized multiple production lines, and also stepped up production of1st of its kind Anti-microbial gloves TRUSHIELD, that protects both surgeons and patients against microbes. A significant production of gloves have been earmarked for government hospitals.

The company has also provisioned for up to 2 months of stock of critical products codes for emergency surgeries like cardio-vascular surgeries and OB-GYN led surgeries, which continue despite the pandemic.

Commenting on the contribution, Mr. Anish Bafna, MD & CEO, Healthium Group said, “The Healthcare industry has been at the forefront in the fight against COVID. While we continue to supportthem withmedical devices and essential consumables by keeping our manufacturing facilities running during Lockdown with due safety precautions, we are also constantly evaluating how we can optimise on our operations and have reduced the time to market. We are acutely aware of the burden on the system that is not only catering to COVID emergencies but other emergency surgeries that need to be prioritised amidst the ongoing stretch and have provisioned essential products to support these.We are committed to work in solidarity with the industrythrough this situation.”

On its efforts towards safeguarding employee health and well-being the company has been organising vaccination drives, mental counselling sessions and several safety measures at the manufacturing facilities including availability of oxygen concentrators in case of need. For the financial security of employees and their families, the Company has announced INR20lakh pay out to the family of the bereaved, in case of loss of life due to COVID and full gratuity payout irrespective of eligibility criteria.The company alreadyhas in place health insurance, GPA, EDLI and term benefits for employees.

Healthium was amongst the first to announceQuarantine leave during the last phase of the pandemic. Additionally reimbursement of vaccine costs, RT PCR, other blood tests and scans have been provided for.As a testimony of its gratitude to employees,the company has paid out increments, incentives and bonuses.

Ms. Kankana Barua, Group CHRO, Healthium further added, “The last 15 months have been a truly testing time for each one of us. Despite the personal commitments and even losses, our employees have been working hard understanding that we are an essential services provider who needs to step up our game in times like these. While our employees work tirelessly towards a mission, we have taken several measures to safeguard them physically, financially and mentally in addition to ensuring that they are adequately rewarded for their efforts.”

The company’s contribution towards community welfare surpasses donation of funds and consumables. Till date, Healthium has distributed 10000 face masks, 154 PPE kits for HCPs, donated surgical consumables to Government hospitals and also associated with 154 hospitals mainly in Tier 3, 4 and 5 towns to extend safe OPD and safe surgery education during the last wave.In addition to donating towards the PM Cares fund, the company continues to educate communities around its plant and campus on COVID appropriate behaviour.

About Healthium Medtech
The Healthium Group consists of Healthium Medtech Pvt. Ltd., one of the largest players in the Indian Medical Devices Market, QNPL, the largest independent manufacturer of surgical suture needles worldwide by volume, and Clinisupplies a leading player in Urology Consumables in the United Kingdom. The Healthium Group has a lineage of 36 years in creating precision based medical devices across the world. With a vision to create access to Precision MedTech for every patient globally, Healthium MedTech is present in over 80 countries, covers 18000+ hospitals across India and has a workforce of over 1500 employees of which 60% are women. Its portfolio includes minimally invasive solutions like Arthroscopy and Endoscopy implants and Ancillary devices, a full range of Absorbable, Non- Absorbable and specialty surgical sutures, wound closure products that include Meshes, Skin staplers, Cardiac Pacing wires and Haemostats. Healthium has manufacturing facilities across India and the company holds over 55 patents in India and the U.S, including those applied for. Backed by stringent R & D norms, the company’s products adhere to the highest global quality standards, having accreditations and approvals from 510k (USFDA), CE & ISO.

HEALTHIUM MEDTECH LTD

(formerly known as Healthium Medtech Private Limited)

472/D, 13th Cross, 4th Phase, Peenya Industrial Area, Peenya Industrial Area Phase IV, Peenya, Bengaluru, Karnataka - 560 058, INDIA

CIN: U03311KA1992PLC013831

contact@healthiummedtech.com

For any queries or complaints write to
care@healthiummedtech.com

Customer care number
+91-80-41868000

DISCLAIMER

“Healthium Medtech Limited is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its equity shares and has filed a draft red herring prospectus (“DRHP”) with the Securities and Exchange Board of India. The DRHP is available on the website of the SEBI at www.sebi.gov.in as well as on the websites of the book running lead managers, ICICI Securities Limited, CLSA India Private Limited, Credit Suisse Securities (India) Private Limited and Nomura Financial Advisory and Securities (India) Private Limited, at www.icicisecurities.com, www.india.clsa.com, www.credit-suisse.com and www.nomuraholdings.com/company/group/asia/india/index.html, respectively, and the websites of the stock exchange(s) at www.bseindia.com and www.nseindia.com, respectively. Any potential investor should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see "Risk Factors" of the RHP / Prospectus, when available. Potential investors should not rely on the DRHP for any investment decision.”

We use cookies to ensure you get the best experience on our website. Click here to view cookie policy